Top

CardioVascular and Interventional Radiology

Published in:

01-04-2013 | Clinical Investigation

Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study

Authors: Shoaib Rafi, Sarat M. Piduru, Bassel El-Rayes, John S. Kauh, David A. Kooby, Juan M. Sarmiento, Hyun S. Kim

Published in: CardioVascular and Interventional Radiology | Issue 2/2013

Abstract

Purpose

To assess the overall survival, efficacy, and safety of radioembolization with yttrium-90 (Y90) for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma (ICC).

Methods

Patients with unresectable standard-chemorefractory ICC treated with Y90 were studied. Survival was calculated from the date of first Y90 procedure. Tumor response was assessed with the Response Evaluation Criteria in Solid Tumors criteria on follow-up computed tomography or magnetic resonance imaging scans. National Cancer Institute Common Terminology Criteria (NCI CTCAE), version 3, were used for complications. Statistical analysis was performed by the Kaplan–Meier estimator by the log rank test.

Results

Nineteen patients underwent a total of 24 resin-based Y90 treatments. Median survival from the time of diagnosis and first Y90 procedure was 752 ± 193 [95 % confidence interval (CI) 374–1130] and 345 ± 128 (95 % CI 95–595) days, respectively. Median survival with Eastern Cooperative Oncology Group (ECOG) performance status 1 (n = 15) and ECOG performance status 2 (n = 4) was 450 ± 190 (95 % CI 78–822) and 345 ± 227 (95 % CI 0–790) days, respectively (p = .214). Patients with extrahepatic metastasis (n = 11) had a median survival of 404 ± 309 (95 % CI 0–1010) days versus 345 ± 117 (95 % CI 115–575) days for patients without metastasis (n = 8) (p = .491). No mortality was reported within 30 days from first Y90 radioembolization. One patient developed grade 3 thrombocytopenia as assessed by NCI CTCAE. Fatigue and transient abdominal pain were observed in 4 (21 %) and 6 (32 %) patients, respectively.

Conclusion

Y90 radioembolization is effective for unresectable standard-chemorefractory ICC.

Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115–125PubMedCrossRef

Patel T (2001) Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33:1353–1357PubMedCrossRef

Shaib YH, Davila JA, McGlynn K, El-Serag HB (2004) Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 40:472–477PubMedCrossRef

Farley DR, Weaver AL, Nagorney DM (1995) “Natural history” of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 70:425–429PubMedCrossRef

Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896–902PubMedCrossRef

Valle J, Wasan H, Palmer DH, for the ABC-02 Trial Investigators et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281PubMedCrossRef

Burger I, Hong K, Schulick R, Georgiades C et al (2005) Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16:353–361PubMedCrossRef

Herber S, Otto G, Schneider J et al (2007) Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Interv Radiol 30:1156–1165CrossRef

Chiou YY, Hwang JI, Chou YH et al (2005) Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J Med Sci 21:304–309PubMedCrossRef

10.

Kim JH, Won HJ, Shin YM, Kim KA, Kim PN (2011) Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 196:W205–W209PubMedCrossRef

11.

Veeze-Kuijpers B, Meerwaldt JH, Lameris JS et al (1990) The role of radiotherapy in the treatment of bile duct carcinoma. Int J Radiat Oncol Biol Phys 18:63–67PubMedCrossRef

12.

Pitt HA, Nakeeb A, Abrams RA et al (1995) Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 221:788–797PubMedCrossRef

13.

Park SY, Kim JH, Yoon HJ et al (2011) Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 66:322–328PubMedCrossRef

14.

Vente MA, Wondergem M, van der Tweel I et al (2009) Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 19:951–959PubMedCrossRef

15.

Ibrahim SM, Mulcahy MF, Lewandowski RJ et al (2008) Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 113:2119–2128PubMedCrossRef

16.

Saxena A, Bester L, Chua TC et al (2009) Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 17:484–491PubMedCrossRef

17.

Hoffmann RT, Paprottka PM, Schön A et al (2012) Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Interv Radiol 35:105–116CrossRef

18.

Salem R, Parikh P, Atassi B et al (2008) Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 31:431–438PubMedCrossRef

19.

Bester L, Salem R (2007) Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. J Vasc Interv Radiol 18:1310–1314PubMedCrossRef

20.

Lewandowski RJ, Sato KT, Atassi B et al (2007) Radioembolization with ⁹⁰Y microspheres: angiographic and technical considerations. Cardiovasc Interv Radiol 30:571–592CrossRef

21.

Kooby DA, Egnatashvili V, Srinivasan S et al (2009) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21:224–230PubMedCrossRef

22.

Salem R, Thurston KG (2006) Radioembolization with ⁹⁰yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 17:1251–1278PubMedCrossRef

23.

Kennedy A, Nag S, Salem R et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium. Int J Radiat Oncol Biol Phys 68:13–23PubMedCrossRef

24.

Chen MF (1999) Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol 14:1144–1149PubMedCrossRef

25.

American Cancer Society (2010) Cancer facts and figures. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-2010

26.

Nathan H, Pawlik TM, Wolfgang CL et al (2007) Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 11:1488–1496PubMedCrossRef

27.

Lieser MJ, Barry MK, Rowland C et al (1998) Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 5:41–47PubMedCrossRef

28.

Miwa S, Miyagawa S, Kobayashi A et al (2006) Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol 41:893–900PubMedCrossRef

29.

Paik KY, Jung JC, Heo JS et al (2008) What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol 23:766–770PubMedCrossRef

30.

Czito BG, Anscher MS, Willett CG (2006) Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 20:873–884

31.

Grady ED (1979) Internal radiation therapy of hepatic cancer. Dis Colon Rectum 22:371–375PubMedCrossRef

Title: Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study
Authors: Shoaib Rafi
Sarat M. Piduru
Bassel El-Rayes
John S. Kauh
David A. Kooby
Juan M. Sarmiento
Hyun S. Kim
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: CardioVascular and Interventional Radiology / Issue 2/2013
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-012-0463-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2013

Management of Postoperative Lymphoceles After Lymphadenectomy: Percutaneous Catheter Drainage With and Without Povidone-Iodine Sclerotherapy

Retrograde Percutaneous Transmetatarsal Artery Access: New Approach for Extreme Revascularization in Challenging Cases of Critical Limb Ischemia

Microwave Ablation of Pulmonary Malignancies Using a Novel High-energy Antenna System

Insertion of Balloon Retained Gastrostomy Buttons: A 5-Year Retrospective Review of 260 Patients

Efficacy and Safety of a Novel Vascular Closure Device (Glubran 2 Seal) After Diagnostic and Interventional Angiography in Patients with Peripheral Arterial Occlusive Disease

Hippocrates Predicted Renal Cryoablation Bleeding Risk in Patients Receiving Anticoagulation